Showing 581-590 of 21412 results for "".
- Human Longevity Lab Will Study Methods to Slow or Reverse Aging - News Centerhttps://reachmd.com/news/human-longevity-lab-will-study-methods-to-slow-or-reverse-aging-news-center/2467331/Scientists want to develop ways to improve human lifespan, so people live longer, healthier lives A comprehensive research protoc
- Gold Nanoparticles Reverse Brain Deficits in Multiple Sclerosis, Parkinson’shttps://reachmd.com/news/gold-nanoparticles-reverse-brain-deficits-in-multiple-sclerosis-parkinsons/2462818/Gold nanocrystals suspended in a water buffer represent a novel therapeutic agent developed by Clene Nanomedicine for neurodegenerative conditions. This nanomedicine, called CNM-Au8, is being investigated to treat patients with multiple sclerosis and Parkinson’s disease in cl
- Study Links Sweet Tooth to Increased Risks of Depression, Diabetes, and Strokehttps://reachmd.com/news/study-links-sweet-tooth-to-increased-risks-of-depression-diabetes-and-stroke/2468419/New research from the University of Surrey reveals a significant link between having a sweet tooth and an elevated risk of depression, diabetes, and stroke. The study, published in the Journal of Translational Medicine, analyzed data from 180,000 participants in the UK Biobank to explore
- AI Spotlights Hidden Diabetes Risk Before Traditional Testshttps://reachmd.com/news/ai-spotlights-hidden-diabetes-risk-before-traditional-tests/2476006/As demonstrated by an AI-driven diabetes model, complex patterns of glucose variability can flag patients at risk for diabetes even when traditional tests appear normal, underscoring an unde
- Phase I Clinical Insights on Obrixtamig: Targeting DLL3-Positive Cancershttps://reachmd.com/news/phase-i-clinical-insights-on-obrixtamig-targeting-dll3-positive-cancers/2483521/In the relentless pursuit to conquer aggressive forms of cancer, obrixtamig represents a beacon of hope for those battling DLL3-positive carcinomas. Small cell lung cancer (SCLC) presents unique challenges in oncologic care, with exploration extending to other DLL3‑positive neuroendocrine t
- Delix Plans Further Trials with Neuroplastogen After Positive Phase I Datahttps://reachmd.com/news/delix-plans-further-trials-with-neuroplastogen-after-positive-phase-i-data/2467418/
- Urinary Podocalyxin May Flag Early Diabetic Nephropathyhttps://reachmd.com/news/urinary-podocalyxin-may-flag-early-diabetic-nephropathy/2488097/Key Takeaways Among adults with T2DM studied in Dhaka, Bangladesh, urinary podocalyxin rose significantly across normoalbuminuric, microalbuminuric, and macroalbuminuric groups. At the main diabetic nephropathy cutoff, urinary podocalyxin classified albuminuric disea
- Brolucizumab in Condor Trial for Proliferative Diabetic Retinopathyhttps://reachmd.com/news/brolucizumab-in-condor-trial-for-proliferative-diabetic-retinopathy/2487676/Key Takeaways Week 54 visual acuity preservation favored brolucizumab over panretinal photocoagulation. No proliferative diabetic retinopathy at week 54 was reported in 63.6% of brolucizumab-treated patients and 22.4% of PRP-treated patients.
- Addressing Cultural Gaps in Diabetes Prevention and Self-Managementhttps://reachmd.com/news/cultural-gaps-diabetes-prevention-management/2485616/Vietnamese American adults at risk for diabetes may feel motivated to change diet and activity habits yet report low readiness to enroll in formal prevention and management programs. A
- Understanding Glucose Levels in Non-Diabetics: New Findings from Continuous Glucose Monitoringhttps://reachmd.com/news/researchers-present-ranges-of-normal-glucose-levels-among-non-diabetic-adults-wearing-continuous-glucose-monitors/2468341/The use of continuous glucose monitors (CGMs) is expanding beyond diabetic populations, with many non-diabetic individuals adopting these devices to track their glucose levels. However, little research has been done to establish normative glucose ranges for non-diabetic users. A r